Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
Timothy J. Brown, Ronac Mamtani, Phyllis A. Gimotty, Thomas B. Karasic, Yu‐Xiao Yang
Topics & Concepts
MedicineAtezolizumabInternal medicineBevacizumabHazard ratioHepatocellular carcinomaCohortProportional hazards modelGastroenterologyOncologyCancerConfidence intervalChemotherapyNivolumabImmunotherapyHepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentCancer Immunotherapy and Biomarkers